179 related articles for article (PubMed ID: 21495926)
1. Magnetic resonance imaging of malignant lymphoma.
Vermoolen MA; Kersten MJ; Fijnheer R; van Leeuwen MS; Kwee TC; Nievelstein RA
Expert Rev Hematol; 2011 Apr; 4(2):161-71. PubMed ID: 21495926
[TBL] [Abstract][Full Text] [Related]
2. Ionising radiation-free whole-body MRI versus (18)F-fluorodeoxyglucose PET/CT scans for children and young adults with cancer: a prospective, non-randomised, single-centre study.
Klenk C; Gawande R; Uslu L; Khurana A; Qiu D; Quon A; Donig J; Rosenberg J; Luna-Fineman S; Moseley M; Daldrup-Link HE
Lancet Oncol; 2014 Mar; 15(3):275-85. PubMed ID: 24559803
[TBL] [Abstract][Full Text] [Related]
3. Whole-body diffusion-weighted imaging: the added value to whole-body MRI at initial diagnosis of lymphoma.
Gu J; Chan T; Zhang J; Leung AY; Kwong YL; Khong PL
AJR Am J Roentgenol; 2011 Sep; 197(3):W384-91. PubMed ID: 21862763
[TBL] [Abstract][Full Text] [Related]
4. [Magnetic resonance imaging in the staging of malignant lymphomas].
Mikhaĭlov AI; Tiurin IE; Panov VO
Vestn Rentgenol Radiol; 2014; (2):60-7. PubMed ID: 25272725
[TBL] [Abstract][Full Text] [Related]
5. A prospective diagnostic accuracy study of 18F-fluorodeoxyglucose positron emission tomography/computed tomography, multidetector row computed tomography, and magnetic resonance imaging in primary diagnosis and staging of pancreatic cancer.
Kauhanen SP; Komar G; Seppänen MP; Dean KI; Minn HR; Kajander SA; Rinta-Kiikka I; Alanen K; Borra RJ; Puolakkainen PA; Nuutila P; Ovaska JT
Ann Surg; 2009 Dec; 250(6):957-63. PubMed ID: 19687736
[TBL] [Abstract][Full Text] [Related]
6. The role of PET in lymphoma.
Jhanwar YS; Straus DJ
J Nucl Med; 2006 Aug; 47(8):1326-34. PubMed ID: 16883013
[TBL] [Abstract][Full Text] [Related]
7. Impact of FDG-PET/CT in the management of lymphoma.
Baba S; Abe K; Isoda T; Maruoka Y; Sasaki M; Honda H
Ann Nucl Med; 2011 Dec; 25(10):701-16. PubMed ID: 22037934
[TBL] [Abstract][Full Text] [Related]
8. Whole-body magnetic resonance imaging and positron emission tomography-computed tomography in oncology.
Schmidt GP; Kramer H; Reiser MF; Glaser C
Top Magn Reson Imaging; 2007 Jun; 18(3):193-202. PubMed ID: 17762383
[TBL] [Abstract][Full Text] [Related]
9. Whole-body MRI, including diffusion-weighted imaging, for the initial staging of malignant lymphoma: comparison to computed tomography.
Kwee TC; van Ufford HM; Beek FJ; Takahara T; Uiterwaal CS; Bierings MB; Ludwig I; Fijnheer R; Nievelstein RA
Invest Radiol; 2009 Oct; 44(10):683-90. PubMed ID: 19724232
[TBL] [Abstract][Full Text] [Related]
10. MRI and PET in monitoring response in lymphoma.
Rahmouni A; Luciani A; Itti E
Cancer Imaging; 2005 Nov; 5 Spec No A(Spec No A):S106-12. PubMed ID: 16361125
[TBL] [Abstract][Full Text] [Related]
11. 18F-FDG PET/CT, 99mTc-MIBI, and MRI in evaluation of patients with multiple myeloma.
Fonti R; Salvatore B; Quarantelli M; Sirignano C; Segreto S; Petruzziello F; Catalano L; Liuzzi R; Rotoli B; Del Vecchio S; Pace L; Salvatore M
J Nucl Med; 2008 Feb; 49(2):195-200. PubMed ID: 18199607
[TBL] [Abstract][Full Text] [Related]
12. Integrating PET and PET/CT into the risk-adapted therapy of lymphoma.
Kasamon YL; Jones RJ; Wahl RL
J Nucl Med; 2007 Jan; 48 Suppl 1():19S-27S. PubMed ID: 17204717
[TBL] [Abstract][Full Text] [Related]
13. PET/CT for therapy response assessment in lymphoma.
Hutchings M; Barrington SF
J Nucl Med; 2009 May; 50 Suppl 1():21S-30S. PubMed ID: 19380407
[TBL] [Abstract][Full Text] [Related]
14. Prospective study of bone marrow infiltration in aggressive lymphoma by three independent methods: whole-body MRI, PET/CT and bone marrow biopsy.
Ribrag V; Vanel D; Leboulleux S; Lumbroso J; Couanet D; Bonniaud G; Aupérin A; Masson F; Bosq J; Edeline V; Fermé C; Pigneur F; Schlumberger M
Eur J Radiol; 2008 May; 66(2):325-31. PubMed ID: 17651934
[TBL] [Abstract][Full Text] [Related]
15. Increased (18)F-fluorodeoxyglucose uptake in benign, nonphysiologic lesions found on whole-body positron emission tomography/computed tomography (PET/CT): accumulated data from four years of experience with PET/CT.
Metser U; Even-Sapir E
Semin Nucl Med; 2007 May; 37(3):206-22. PubMed ID: 17418153
[TBL] [Abstract][Full Text] [Related]
16. F-18 2-fluoro-2-deoxy-glucose positron emission tomography/computed tomography for the detection of radicular and peripheral neurolymphomatosis: correlation with magnetic resonance imaging and ultrasound.
von Falck C; Rodt T; Joerdens S; Waldeck S; Kiesel H; Knapp WH; Galanski M
Clin Nucl Med; 2009 Aug; 34(8):493-5. PubMed ID: 19617723
[TBL] [Abstract][Full Text] [Related]
17. Role of WB-MR/DWIBS compared to (18)F-FDG PET/CT in the therapy response assessment of lymphoma.
Maggialetti N; Ferrari C; Minoia C; Asabella AN; Ficco M; Loseto G; De Tullio G; de Fazio V; Calabrese A; Guarini A; Rubini G; Brunese L
Radiol Med; 2016 Feb; 121(2):132-43. PubMed ID: 26349573
[TBL] [Abstract][Full Text] [Related]
18. PET/CT for the staging and follow-up of patients with malignancies.
Poeppel TD; Krause BJ; Heusner TA; Boy C; Bockisch A; Antoch G
Eur J Radiol; 2009 Jun; 70(3):382-92. PubMed ID: 19406595
[TBL] [Abstract][Full Text] [Related]
19. Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications.
Kwee TC; Takahara T; Ochiai R; Koh DM; Ohno Y; Nakanishi K; Niwa T; Chenevert TL; Luijten PR; Alavi A
J Nucl Med; 2010 Oct; 51(10):1549-58. PubMed ID: 20847177
[TBL] [Abstract][Full Text] [Related]
20. Whole-body diffusion-weighted magnetic resonance imaging versus FDG-PET/CT for initial lymphoma staging: systematic review on diagnostic test accuracy studies.
Regacini R; Puchnick A; Shigueoka DC; Iared W; Lederman HM
Sao Paulo Med J; 2015; 133(2):141-50. PubMed ID: 25789779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
